SEARCH

SEARCH BY CITATION

References

  • 1
    Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27:11491156.MEDLINE
  • 2
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson A. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282:103107.MEDLINE
  • 3
    Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon-alfa on viral turnover. Hepatology 1998; 28:245252.MEDLINE
  • 4
    Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28:960964.MEDLINE
  • 5
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:14851492.MEDLINE
  • 6
    Poynard T, Marcellin P, Lee SS, Niederau, C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:14261432.MEDLINE
  • 7
    Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. Hepatology 2000; 32:889896.MEDLINE
  • 8
    Bekkering FC, Brouwer JT, Schalm SW, Elewaut A. Hepatitis C: viral kinetics. Hepatology 1997; 26:16911693.MEDLINE
  • 9
    Lam NP, Neuman AU, Gretch DR, Wiley TE, Perelson AS, Layden TS. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226231.MEDLINE
  • 10
    Fried MW, Shiffman M, Sterling RK, Weinstein J, Crippin J, Garcia G, E Wright TL, et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95:32253229.MEDLINE
    Direct Link:
  • 11
    Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996; 24:103440.MEDLINE
  • 12
    Di Marco V, Lo Iacono O, Camma C, Almasio PL, Vaccaro A, Fuschi P, et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol 1997; 51:1724.MEDLINE
  • 13
    Yoshioka K, Yano M, Kusakabe A, Hirofuji H, Fuji A, Kuriki J, et al. Randomized controlled trial of lymphoblastoid interferon alpha for chronic hepatitis C (comparison of 9-MU and 6-MU doses). IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya University School of Medicine. Am J Gastroenterol 1999; 94:164168.MEDLINE
  • 14
    Tassopoulos NC, Karvountzis G, Touloumi G, Delladetsima JK, Papatheodoridis GV, Katsoulidou A, Retalis G, et al. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol 1996; 91:17341738MEDLINE
  • 15
    Pol S, Nalpas B, Bourliere M, Couzigou P, Tran A, Abergel A, Zarski JP, et al. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000; 31:13381344.MEDLINE
  • 16
    Ferenci P, Renner F, Müller Ch, Stauber R, Kessler H, Penner E, Wrba F, et al. Empfehlungen zur Behandlung der Virushepatitis. Konsensus—Konferenz der ÖGGH. Z Gastroenterol 1999; 37:XXIXXVII.
  • 17
    Hazard-Munro B. Statistical Methods for Health Care Research. Lippincott, Philadelphia, 1991.
  • 18
    Eibl N, Gschwantler M, Ferenci P, Eibl MM, Weiss W, Schernthaner G. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastro Hep 2001; 13:295298.
  • 19
    Carithers RL, Zeuzem S, Manns MP, McHutchison JG, Perrillo RP, Bailey R, Ling MS, et al. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin. Hepatology 2000; 32(Suppl):317A.
  • 20
    Bjoro K, Bell H, Hellum K, Myrvang B, Skaug K. Randomized trial of IFN-α induction and ribavirin vs. standard IFN-α and ribavirin from chronic hepatitis C in previously untreated patients. Hepatology 2000; 32(Suppl):317A.
  • 21
    National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997; 26(Suppl 1):2S10S.MEDLINE
  • 22
    EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30:956961.MEDLINE
  • 23
    Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32:818823.MEDLINE
  • 24
    Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel Th, Wrba F, Mueller Ch, et al. A pilot study on primary interferon-resistance as predictor of nonresponse to treatment in chronic hepatitis C virus genotype 1 infection. Lancet 2001 (in press).
  • 25
    Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33:419423.MEDLINE
  • 26
    Herxenberg LA, Moore WA, de Rosa SC. Estimation of missing values. Lancet 1999; 354:686.MEDLINE
  • 27
    Ferenci P, Dragosics P, Pauser G: Non-A-Non-B-Hepatitisepidemie bei einer Plasmapheresestelle. Verh Dtsch Ges Inn Med 1979, 85:553556.
  • 28
    Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis center. Gut 1999; 44:563567.MEDLINE